CMML Leukemia: Symptoms, Diagnosis, and Care

CMML leukemia, also called chronic myelomonocytic leukemia, is a rare cancer of the blood-forming cells in bone marrow. It can cause low blood counts, an increased number of monocytes, and an enlarged spleen; treatment is personalized according to symptoms, blood counts, genetic findings and overall health.

Overview: What Is CMML Leukemia?

CMML leukemia is short for chronic myelomonocytic leukemia, a rare cancer that begins in the bone marrow, where blood cells are made. It particularly affects myeloid cells, which normally develop into several types of blood cells, including monocytes. In CMML, abnormal cells multiply and mature unevenly, leading to a persistently raised monocyte count in the blood and, in many people, low levels of healthy blood cells.

CMML is classified as a myelodysplastic/myeloproliferative neoplasm (MDS/MPN). This means it has features of myelodysplastic disorders, in which blood cells are made poorly, and myeloproliferative disorders, in which some blood cells are produced in excess. The condition is chronic, but its course varies considerably between individuals.

Some people are diagnosed after a routine blood test before they notice symptoms. Others have effects related to anemia, infection risk, bleeding, or an enlarged spleen. CMML may remain relatively stable for a period of time, but it needs specialist follow-up because it can become more active and may transform into acute myeloid leukemia (AML) in some cases.

How CMML May Affect the Body

The bone marrow normally produces red blood cells to carry oxygen, white blood cells to help fight infection, and platelets to help blood clot. In CMML, the abnormal clone of cells can crowd out normal blood production. This may result in anemia, low platelet levels, or low levels of infection-fighting white cells, even though the total white blood cell count can sometimes be high.

Doctors often describe CMML as having either a dysplastic or a proliferative pattern. A dysplastic pattern is more often associated with low blood counts and ineffective blood-cell production. A proliferative pattern is more often associated with a higher white blood cell count, constitutional symptoms such as sweating or weight loss, and enlargement of the spleen. These patterns can overlap and can change over time.

The spleen filters blood and supports immune function. When abnormal cells accumulate, it may enlarge and cause fullness or discomfort under the left ribs, reduced appetite, or feeling full soon after eating. Not everyone with CMML develops spleen enlargement, and symptoms alone cannot determine how the condition is behaving.

Symptoms and Possible Signs

CMML symptoms are often nonspecific, meaning they can also occur with many non-cancerous health conditions. Symptoms commonly reflect anemia, reduced platelets, infection susceptibility, or the effects of increased white blood cells. Their presence and severity do not always directly match a single blood-test result.

• Persistent tiredness, weakness, reduced exercise tolerance, dizziness, or shortness of breath related to anemia
• Frequent, severe, or slow-to-resolve infections, sometimes with fever
• Easy bruising, nosebleeds, bleeding gums, or tiny red-purple skin spots caused by low platelets
• Unexplained weight loss, night sweats, fever, or reduced appetite
• Fullness, pain, or pressure in the upper-left abdomen that may occur with an enlarged spleen

Many of these symptoms can have other explanations, including nutritional deficiencies, viral illnesses, medication effects, or inflammatory conditions. A doctor can interpret them alongside the full blood count, physical examination and any necessary follow-up tests. People should not try to diagnose CMML from symptoms alone.

Causes and Risk Factors

CMML develops when acquired genetic changes occur in a blood-forming stem cell in the bone marrow. These changes are not usually inherited from a parent and are not caused by something a person did. They can alter how cells grow, mature and communicate, allowing an abnormal group of cells to gradually become dominant.

Gene changes frequently found in CMML involve pathways that regulate cell signaling, DNA modification, and blood-cell development. Testing for these changes can help support the diagnosis, provide prognostic information, and occasionally guide treatment planning. A genetic change found in leukemia cells is different from an inherited genetic condition affecting all cells in the body.

CMML is diagnosed most often in older adults and is more common in men than women. Prior exposure to chemotherapy or radiation for another cancer may contribute to a small proportion of cases. However, most people with CMML do not have a clear identifiable cause, and there is no established lifestyle measure that reliably prevents it.

Diagnosis and Risk Assessment

Diagnosis usually begins with a complete blood count and blood film, which examines blood cells under a microscope. A key finding is persistent monocytosis: an increased number of monocytes over time. Doctors generally confirm that this change is sustained rather than due to a short-term infection, inflammation, autoimmune disease, or another reactive cause.

A bone marrow aspiration and biopsy are central tests. They show how blood cells are developing, assess the proportion of immature cells called blasts, and help identify dysplasia, or abnormal cell development. In CMML, blasts remain below the level used to diagnose AML. Cytogenetic and molecular tests look for chromosome and gene changes and help rule out other myeloid cancers that can resemble CMML.

Following diagnosis, a hematologist estimates risk by considering blood counts, blast percentage, chromosome findings, gene mutations, symptoms, and general health. Risk assessment is not a prediction with certainty. Instead, it helps clinicians discuss the likely behavior of the condition, choose the intensity of treatment, and decide how closely to monitor for change.

Treatment Options and Ongoing Care

CMML treatment is individualized. For a person who feels well and has stable blood counts, active monitoring may be appropriate. This involves scheduled clinical reviews and blood tests, allowing treatment to begin if symptoms emerge, blood counts worsen, the spleen enlarges, or the disease shows signs of becoming more active. Monitoring is an active care plan, not an absence of care.

Supportive care may include red blood cell or platelet transfusions when needed, treatment of infections, and medicines that support blood-cell production in selected situations. For proliferative CMML with high white blood cell counts or symptoms from spleen enlargement, cytoreductive treatment such as hydroxyurea may help control cell counts and improve symptoms. The best approach depends on the individual’s blood counts and treatment goals.

Hypomethylating medicines, including azacitidine or decitabine, may be considered for people with clinically significant cytopenias, increased blasts, or higher-risk disease. They are given in repeated treatment cycles and require close blood-count monitoring because they can temporarily lower counts. A hematology team can explain expected benefits, limitations, and potential adverse effects in the context of each person’s condition.

An allogeneic stem cell transplant, using stem cells from a donor, is currently the only treatment with curative potential. It is generally considered for selected medically fit people whose disease risk and overall health make the possible benefit outweigh substantial risks, including infection, graft-versus-host disease, and treatment-related complications. Clinical trials may also be appropriate for eligible patients. Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals evaluate and treat blood cancers for international patients.

Living With CMML and When to Seek Medical Care

Regular hematology appointments are important even when CMML is not causing symptoms. People can support their care by attending blood-test visits, keeping a record of fatigue, fever, bleeding, infections or abdominal symptoms, and discussing all medicines and supplements with their clinical team. A balanced diet, regular activity suited to energy levels, sleep, and emotional support can help overall wellbeing, but they do not replace medical treatment.

People should contact their medical team promptly for a fever, signs of infection, unusual or prolonged bleeding, new widespread bruising, rapidly worsening fatigue, shortness of breath, or new abdominal pain or fullness. The care team may give individualized instructions on what temperature or symptoms require urgent assessment, particularly during treatment that lowers blood counts.

Emergency medical care is appropriate for severe breathlessness, chest pain, confusion, fainting, uncontrolled bleeding, or a high fever with feeling very unwell. These symptoms do not always mean CMML has progressed, but timely assessment is important. A person with new unexplained blood-count abnormalities should arrange a medical evaluation rather than waiting for symptoms to resolve on their own.

Frequently asked questions